Sheehan F H, Doerr R, Schmidt W G, Bolson E L, Uebis R, von Essen R, Effert S, Dodge H T
Cardiovascular Research and Training Center, University of Washington, Seattle 98195.
J Am Coll Cardiol. 1988 Aug;12(2):289-300. doi: 10.1016/0735-1097(88)90397-x.
Thrombolytic therapy for acute myocardial infarction reduces early mortality, but full recovery of left ventricular function after reperfusion is delayed. Therefore, the relations among reperfusion, survival and the time course of left ventricular functional recovery were examined in 226 patients treated with intracoronary streptokinase; 77% (134 patients) had sustained reperfusion and 31 patients had no reperfusion or had reocclusion by day 3. Wall motion was measured from contrast ventriculograms performed in the acute period and 3 days later in the central and peripheral infarct regions and the noninfarct region by the centerline method in 165 patients. Patients with reperfusion had better survival (p less than 0.05, mean follow-up 4.5 years) and a higher ejection fraction at 3 days (52 +/- 12 versus 46 +/- 10%, p less than 0.02) attributable to a significantly different change in peripheral infarct region function between the acute and 3 day studies (0.1 +/- 1.0 versus -0.3 +/- 0.9 SD, p less than 0.05). These early functional changes were significant in patients with anterior myocardial infarction and showed similar trends in those with inferior myocardial infarction. On Cox regression analysis, function measured at 3 days was more predictive of survival than was function measured acutely (chi square for acute ejection fraction = 11.48 versus 24.59 at 3 days). Although, as previously reported, greater than 45% of total recovery of left ventricular function occurs later, the ejection fraction achieved by day 3 is already predictive of survival. Thus, the mechanism by which successful thrombolytic therapy enhances survival is improvement of regional and global left ventricular function early after acute myocardial infarction.
急性心肌梗死的溶栓治疗可降低早期死亡率,但再灌注后左心室功能的完全恢复会延迟。因此,我们对226例接受冠状动脉内链激酶治疗的患者进行了研究,以探讨再灌注、生存率与左心室功能恢复时间进程之间的关系;77%(134例患者)实现了持续再灌注,31例患者在第3天时未实现再灌注或发生了再闭塞。在急性期以及3天后,对165例患者通过中心线法从中央和外周梗死区域以及非梗死区域的对比心室造影测量壁运动。实现再灌注的患者生存率更高(p<0.05,平均随访4.5年),且在第3天时射血分数更高(52±12%对46±10%,p<0.02),这归因于急性期与第3天研究之间外周梗死区域功能的显著不同变化(0.1±1.0对-0.3±0.9标准差,p<0.05)。这些早期功能变化在前壁心肌梗死患者中显著,在下壁心肌梗死患者中也呈现类似趋势。在Cox回归分析中,第3天测量的功能比急性期测量的功能更能预测生存率(急性期射血分数的卡方值=11.48,而第3天时为24.59)。尽管如先前报道的那样,左心室功能总恢复的45%以上发生在后期,但第3天达到的射血分数已可预测生存率。因此,成功的溶栓治疗提高生存率的机制是急性心肌梗死后早期区域和整体左心室功能的改善。